India's pharmaceutical industry is poised for significant growth, with its share in the global market expected to rise to 5 ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 ...

Currently valued at around USD 55 billion, the Indian pharma market is expected to more than double over the next six years, reaching an estimated USD 120 billion to USD 130 billion. By 2047, the ...

Dilip Shanghvi, Founder and Managing Director of Sun Pharmaceutical Industries, has indicated potential plans to segment the company's operations into distinct verticals. This strategic consideration ...

Indian pharmaceutical and steel sectors show resilience against proposed US trade tariffs. Sun Pharma's Shanghvi indicates ...

India’s pharmaceutical sector is at a pivotal ... it translates into a significant growth opportunity. However, Bora emphasized that India cannot compete on cost with China at the moment. “China’s ...

While foreign investors have been reducing their exposure to Indian pharma, some leading domestic institutional investors ...

However, P V Appaji, former director general of Pharmexcil finds that the interest of Indian companies to get approvals for ...

The e-pharma market is undergoing remarkable expansion and is expected to surge at a compounded annual growth rate of 15.51% ... Key Market Drivers The e-pharma industry's growth is spearheaded ...

The company is focusing on high-growth segments like injectables and complex generics for growth in US market.